Menu

Update: Iranian Researcher Detained at US Airport

The cancer scientist and his family have been sent home, and an official claims that his detention was not triggered by the Trump travel ban.

Jul 10, 2017
Bob Grant

FLICKR, HILDGRIMUpdate (July 13): Dehnavi and his family were sent back to Iran after being held at Boston’s Logan International Airport by US Customs and Border Protection (CBP) for several hours earlier this week.

“This individual was deemed inadmissible to the U.S. based on information discovered during the [customs] inspection for reasons unrelated to the [Trump administration’s] Executive Order,” the CBP says in a statement reported by several news outlets, including the Boston Globe.

According to the Associated Press and other media outlets, Iranian state television showed footage today of Dehnavi serving as the head of a student branch of a voluntary paramilitary militia in Iran, several years ago.

The television report also included a comment from Dehnavi, the Associated Press reported: “The topic of our research was health and saving ill people fighting cancer from this dangerous disease, but they didn’t allow us entry, despite, as I mentioned, all the efforts made by the American academic community.”

Officials have detained an Iranian cancer researcher at Logan International Airport in Boston since yesterday (July 10). His wife and three young children travelled from Iran with the scientist, Mohsen Dehnavi, who was hoping to start work as a visiting scholar at Boston Children’s Hospital.

“Boston Children’s hopes that this situation will be quickly resolved and Dr. Dehnavi and his family will be released and allowed to enter the U.S.,” Rob Graham, hospital spokesperson, tells STAT.

Dehnavi’s detention comes after the US Supreme Court upheld last month a twice-revised executive order from President Donald Trump that sought to ban travel to the U.S. for residents of several Muslim-majority countries, including Iran. The Court ruled, however, that current visa holders would be allowed to travel to and from the U.S. and that “a worker who accepted an offer of employment from an American company or a lecturer invited to address an American audience” would also be exempt from the travel ban. This alteration to the Trump travel ban gave international researchers some hope that they’d be able to travel freely to the U.S.

See “Supreme Court Reinstates Trump Travel Ban

According to the Boston Globe, Dehnavi was entering the U.S. on a J-1 visa—commonly issued to students and other academics studying or working at American universities—that he had secured back in May. It’s not clear whether the travel ban is to blame, but as STAT notes, the president of the president of the National Iranian American Council holds the policy responsible.

A friend of Dehnavi, Boston Children’s researcher Mohammad Rashidan, tells STAT that officials at Logan International told him the Iranian scientist and his family would likely be sent back to Iran today and would need to complete further paperwork before being allowed into the U.S. “I don’t really know what the source of the problem is,” Rashidan, who was supposed to pick up the Dehnavi family at the airport yesterday, tells STAT. “They were so worried.”

Editor’s note (July 13): The headline and subhead of this article were updated to include news of Dehnavi’s return to Iran.

February 2019

Big Storms Brewing

Can forests weather more major hurricanes?

Marketplace

Sponsored Product Updates

Bio-Rad Releases First FDA-Cleared Digital PCR System and Test for Monitoring Chronic Myeloid Leukemia Treatment Response
Bio-Rad Releases First FDA-Cleared Digital PCR System and Test for Monitoring Chronic Myeloid Leukemia Treatment Response
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced that its QXDx AutoDG ddPCR System, which uses Bio-Rad’s Droplet Digital PCR technology, and the QXDx BCR-ABL %IS Kit are the industry’s first digital PCR products to receive U.S. Food and Drug Administration (FDA) clearance. Used together, Bio-Rad’s system and kit can precisely and reproducibly monitor molecular response to treatment in patients with chronic myeloid leukemia (CML).
Bio-Rad Showcases New Automation Features of its ZE5 Cell Analyzer at SLAS 2019
Bio-Rad Showcases New Automation Features of its ZE5 Cell Analyzer at SLAS 2019
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) today showcases new automation features of its ZE5 Cell Analyzer during the Society for Laboratory Automation and Screening 2019 International Conference and Exhibition (SLAS) in Washington, D.C., February 2–6. These capabilities enable the ZE5 to be used for high-throughput flow cytometry in biomarker discovery and phenotypic screening.
Andrew Alliance and Sartorius Collaborate to Provide Software-Connected Pipettes for Life Science Research
Andrew Alliance and Sartorius Collaborate to Provide Software-Connected Pipettes for Life Science Research
Researchers to benefit from an innovative software-connected pipetting system, bringing improved reproducibility and traceability of experiments to life-science laboratories.
Corning Life Sciences to Feature 3D Cell Culture Technologies at SLAS 2019
Corning Life Sciences to Feature 3D Cell Culture Technologies at SLAS 2019
Corning Incorporated (NYSE: GLW) will showcase advanced 3D cell culture technologies and workflow solutions for spheroids, organoids, tissue models, and applications including ADME/toxicology at the Society for Laboratory Automation and Screening (SLAS) conference, Feb. 2-6 in Washington, D.C.